A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Not Recruiting

Trial ID: NCT02127710


This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.

Official Title

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Alice C. Fan
Alice C. Fan

Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion criteria

   1. Provision of informed consent prior to any study specific procedures, sampling and

   2. Histologically confirmed PRCC, which is locally advanced or metastatic.

   3. Availability of an archival tumor sample or a pre-treatment fresh tumor sample for
   confirmation of PRCC by a central laboratory and other biomarker

   4. Treatment naïve or have failed on previous treatment for PRCC. Previous treatments may
   include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib,
   temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a,
   Interleukin-2), chemotherapy or a combination of chemoimmunotherapy.

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

   6. At least one lesion, not previously irradiated, and not chosen for a biopsy if
   performed during the screening period that can be accurately measured at baseline and
   which is suitable for accurate repeated measurements.

   7. Adequate hematological function defined as:

      1. Absolute neutrophil count ≥1500/μL

      2. Haemoglobin ≥9 g/dL

      3. Platelets ≥100,000/μL

   8. Adequate liver function defined as:

      1. Alanine aminotransferase and aspartate aminotransferase ≤2.5 x the upper limit of
      normal (ULN)

      2. Total bilirubin ≤1.5 x ULN

   9. Adequate renal function defined as glomerular filtration rate ≥ 40 mL/min,

10. Adequate coagulation parameters, defined as International Normalisation Ratio <1.5 x
   ULN or activated partial thromboplastin time <1.5 x ULN.

11. Patients with known tumor thrombus or deep vein thrombosis are eligible if stable on
   low molecular weight heparin for ≥4 weeks.

12. Females should be using adequate contraceptive measures should not be breast feeding,
   and must have a negative pregnancy test prior to start of dosing if of childbearing
   potential or must have evidence of non-childbearing potential

13. Male patients should be willing to use barrier contraception, i.e. condoms.

14. Ability to swallow and retain oral medications.

15. Predicted life expectancy ≥12 weeks.

16. Aged at least 18 years.

17. Willingness and ability to comply with study and follow-up procedures.

18. Ability to understand the nature of this study and give written informed consent.

Exclusion criteria

   1. Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational
   agents <21 days of the first dose of study treatment. Most recent targeted therapy <14
   days of the first dose of study treatment.

   2. Unresolved toxicities from any prior therapy greater than Common Terminology Criteria
   for Adverse Events Grade 1 at the time of starting study treatment with the exception
   of alopecia.

   3. Prior or current treatment with a cMet inhibitor

   4. Strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4), strong inhibitors of
   cytochrome P450 1A2 (CYP1A2), or CYP3A4 substrates with a narrow therapeutic range
   within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)

   5. Wide field radiotherapy (including therapeutic radioisotopes such as strontium-89)
   administered ≤28 days or limited field radiation for palliation ≤7 days prior to
   starting study drug or has not recovered from side effects of such therapy

   6. Major surgical procedures ≤28 days of beginning study drug or minor surgical
   procedures ≤7 days. No waiting is required following port-a-cath placement.

   7. Previously untreated brain metastases.

   8. Current leptomeningeal metastases or spinal cord compression due to disease.

   9. Acute or chronic liver or pancreatic disease.

10. Uncontrolled diabetes mellitus.

11. Gastrointestinal disease or other condition that will interfere significantly with the
   absorption, distribution, metabolism, or excretion of oral therapy

12. Any of the following cardiac diseases currently or within the last 6 months:

      1. Unstable angina pectoris

      2. Congestive heart failure (New York Heart Association ≥ Grade 2)

      3. Acute myocardial infarction

      4. Stroke or transient ischemic attack

13. Inadequately controlled hypertension (i.e., systolic blood pressure >160 mmHg or
   diastolic blood pressure >100 mmHg) (patients with values above these levels must have
   their blood pressure controlled with medication prior to starting treatment).

14. Mean resting correct QT interval (QTc) >470 msec obtained from triplicate

15. Any clinically important abnormalities in rhythm, conduction or morphology of resting
   electrocardiograms, e.g. complete left bundle branch block, third degree heart block,
   second degree heart block, PR interval >250 msec.

16. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
   such as heart failure, hypokalaemia, congenital or familial long QT syndrome or family
   history of unexplained sudden death under 40 years of age or any concomitant
   medications known to prolong QT interval.

17. Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular
   weight heparin is allowed.

18. Serious active infection at the time of treatment, or another serious underlying
   medical condition that would impair the ability of the patient to receive protocol

19. Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.

20. Presence of other active cancers, or history of treatment for invasive cancer ≤5years.
   Patients with Stage I cancer who have received definitive local treatment at least 3
   years previously, and are considered unlikely to recur are eligible. All patients with
   previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are
   patients with history of non-melanoma skin cancer.

21. Psychological, familial, sociological, or geographical conditions that do not permit
   compliance with the protocol.


drug: AZD6094

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts